Ana Espinosa
Dr. Ana Espinosa is Chief Operating Officer at Miramoon Pharma, with over two decades of experience spanning developmental neuroscience, neurodegeneration research, and regenerative therapies, combined with a solid track record in the pharmaceutical and cosmetic industries. She holds a PhD in Neuroscience from Miguel Hernández University of Elche, a Master’s degree in Clinical Analysis, and a BS in Biology with a specialization in Biotechnology.
Her career includes research positions at leading international institutions such as The Scripps Research Institute (San Diego, USA), University of California San Francisco, Institut Jacques Monod (Paris), and Miguel Hernández University. Her scientific contributions include key discoveries in thalamocortical circuit development, neuronal migration, neuroplasticity, and stem cell–based therapies applied to neurodegenerative diseases, with numerous publications in high-impact journals including Science, Neuron, Development, and Frontiers in Neuroanatomy.
Transitioning to industry in 2020, Dr. Espinosa served as Operations Manager at AntalGenics, leading R&D strategies, funding acquisition, quality management systems, and financial operations. At Miramoon Pharma, she leads multidisciplinary teams, coordinates regulatory activities with the European Medicines Agency, manages strategic partnerships, and oversees corporate financial operations. She also represents Spain on the Management Committee of the COST Action Retina4Future, a pan-European initiative accelerating innovation in the diagnosis and treatment of retinal diseases through collaborative networks and rapid translation of scientific advances into clinical applications.
Her leadership blends deep scientific expertise with strategic vision, driving innovation from the laboratory to patient-oriented solutions.
